Genetics can help determine whether a person is likely to quit smoking on his or her own or need medication to improve the chances of success, according to research published in American Journal of Psychiatry.
Researchers say the study moves health care providers a step closer to one day providing more individualized treatment plans to help patients quit smoking.
The study was supported by multiple components of the National Institutes of Health, including the National Institute on Drug Abuse (http://www.drugabuse.gov) (NIDA), the National Human Genome Research Institute (http://www.genome.gov), the National Cancer Institute (http://www.cancer.gov), and the Clinical and Translational Science Awards program, administered by the National Center for Advancing Translational Sciences (http://www.ncats.nih.gov).
"This study builds on our knowledge of genetic vulnerability to nicotine dependence, and will help us tailor smoking cessation strategies accordingly," said NIDA Director Nora D. Volkow, M.D.
Volkow continued, "It also highlights the potential value of genetic screening in helping to identify individuals early on and reduce their risk for tobacco addiction and its related negative health consequences."
Researchers focused on specific variations in a cluster of nicotinic receptor genes, CHRNA5-CHRNA3-CHRNB4, which prior studies have shown contribute to nicotine dependence and heavy smoking.
Using data obtained from a previous study supported by the National Heart Lung and Blood Institute (https://biolincc.nhlbi.nih.gov/studies/aric/), researchers showed that individuals carrying the high-risk form of this gene cluster reported a 2-year delay in the median quit age compared to those with the low-risk genes. This delay was attributable to a pattern of heavier smoking among those with the high risk gene cluster.
The researchers then conducted a clinical trial, which confirmed that persons with the high-risk genes were more likely to fail in their quit attempts compared to those with the low-risk genes when treated with placebo.
However, medications approved for nicotine cessation (such as nicotine replacement therapies or bupropion) increased the likelihood of abstinence in the high risk groups.
Those with the highest risk had a three-fold increase in their odds of being abstinent at the end of active treatment compared to placebo, indicating that these medications may be particularly beneficial for this population.
"We found that the effects of smoking cessation medications depend on a person's genes," said first author Li-Shiun Chen, M.D., of the Washington University School of Medicine, St. Louis.
Chen continued, "If smokers have the risk genes, they don't quit easily on their own and will benefit greatly from the medications. If smokers don't have the risk genes, they are likely to quit successfully without the help of medications such as nicotine replacement or bupropion."